November 7, 2016 / 9:42 PM / 10 months ago

BRIEF-Zogenix Q3 revenue $6.6 mln

Nov 7 (Reuters) - Zogenix Inc

* “Expects its cash runway to extend through 2017”

* Research and development expenses are now expected to be $42-44 million for full year 2016

* Zogenix Inc - cohort 2 (efficacy and safety assessment) in study 1504 for efficacy and safety of zx008 is expected to begin by end of 2016

* Zogenix provides corporate update and reports third quarter 2016 financial results

* Q3 loss per share $0.69

* Q3 revenue $6.6 million

* Q3 earnings per share view $-0.96 -- Thomson Reuters I/B/E/S

* Q3 revenue view $3.1 million -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below